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Abstract
Introduction: Outcome studies in patients with acute kidney injury (AKI) have focused on differences between
modalities of renal replacement therapy (RRT). The outcome of conservative treatment, however, has never been
compared with RRT.
Methods: Nine Belgian intensive care units (ICUs) included all adult patients consecutively admitted with serum
creatinine >2 mg/dl. Included treatment options were conservative treatment and intermittent or continuous RRT.
Disease severity was determined using the Stuivenberg Hospital Acute Renal Failure (SHARF) score. Outcome
parameters studied were mortality, hospital length of stay and renal recovery at hospital discharge.
Results: Out of 1,303 included patients, 650 required RRT (58% intermittent, 42% continuous RRT). Overall results
showed a higher mortality (43% versus 58%) as well as a longer ICU and hospital stay in RRT patients compared to
conservative treatment. Using the SHARF score for adjustment of disease severity, an increased risk of death for
RRT compared to conservative treatment of RR = 1.75 (95% CI: 1.4 to 2.3) was found. Additional correction for
other severity parameters (Acute Physiology And Chronic Health Evaluation II (APACHE II), Sequential Organ Failure
Assessment (SOFA)), age, type of AKI and clinical conditions confirmed the higher mortality in the RRT group.
Conclusions: The SHARF study showed that the higher mortality expected in AKI patients receiving RRT versus
conservative treatment can not only be explained by a higher disease severity in the RRT group, even after
multiple corrections. A more critical approach to the need for RRT in AKI patients seems to be warranted.
Introduction
Acute kidney injury (AKI) occurs in up to 25% of criti-
cally ill patients admitted to the Intensive Care Unit
(ICU) [1]. Despite well-established supportive care and
technical advances in renal replacement therapy (RRT),
mortality remains remarkably high in these patients.
A review by YP Ympa and colleagues, including 80 stu-
dies covering 15,897 patients, revealed that mortality
rates remained unchanged at around 50% over the last
50 years [2]. On the other hand, recent observations
pointed to the relative decline of death rates attributable
to AKI, despite a rise in the occurrence of AKI [3,4].
Conservative AKI treatment includes management of
volume, electrolyte and acid-base homeostasis and speci-
fic drug management. Renal replacement therapy (RRT)
is indicated for management of specific problems such
as volume overload, hyperkalemia, acidosis and symp-
toms of uremia. However, hard data remain absent or
conflictive regarding the timing to start dialysis [5].
Moreover, there is a consensus that RRT is life saving
and not starting RRT will lead to death in severely ill
AKI patients, but data are lacking to generalize this opi-
nion. Research focused completely on the choice and
the dose of RRT modality and particularly results of
comparative studies between daily IRRT (intermittent
hemodialysis) or CRRT (continuous veno-venous hemo-
filtration) remained a matter of debate during the last
decades [6-8]. In recent years, several controlled studies
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[9-12] and meta-analysis [13,14] showed similar benefit
with either dialysis modality. Critics of the published
studies, however, pointed to shortcomings such as lack
of power, selection bias and disregarding differences in
disease severity [10,15-17].
Within the Stuivenberg Hospital Acute Renal Failure
(SHARF) project, we developed and validated a specific
severity scoring system for AKI [18,19]. In this new,
large scaled, prospective study (SHARF 4), we used the
SHARF score to correct for differences in disease sever-
ity comparing different treatment modalities in AKI
patients admitted to the ICU. The SHARF 4 study
included a randomized clinical trial part with results on
the comparison between IRRT and CRRT reported else-
where [20]. This paper will focus on the overall observa-
tional results, comparing ICU and hospital outcome of
AKI patients with conservative therapy or either treated
with intermittent or continuous dialysis techniques.
Materials and methods
Selection of centers
Belgian ICUs were invited to participate in the SHARF4
study if they belonged to a hospital with at least 600
beds having a chronic dialysis unit and if they per-
formed RRT treatment in at least 30 AKI patients dur-
ing the last year. They qualified for participation if both
intermittent and continuous RRT techniques belonged
to their common practice. A center questionnaire was
sent to candidate centers in order to check qualifying
criteria.
Selection of patients
All adult patients consecutively admitted to the ICU and
having a serum creatinine >2 mg/dl were included.
Patients with pre-existing chronic renal disease, defined
as a serum creatinine above 1.5 mg or with clearly
reduced kidney size on ultrasound, were excluded. In all
included patients, disease severity was defined by calcu-
lating the SHARF score [19] and patients were classified
in one of the SHARF severity classes accordingly
(SHARF <30, 30 to 60, >60).
Allocation of treatment
The decision to treat conservatively or to start RRT was
at the discretion of the responsible physician, taking
into account the rules of good clinical practice in this
field. Patients in need of renal replacement therapy were
assigned to daily IRRT (intermittent hemodialysis during
four to six hours daily) or CRRT (continuous veno-
venous hemofiltration) after randomization or according
to local practice, if one of the predefined contraindica-
tions for randomization was present. The techniques
used to perform RRT were in agreement with the stan-
dard procedures of the participating hospitals [20].
Data collection
Basic data collection included demographic data, cause
and type of AKI, type of primary disease, body weight
and length and daily serum creatinine levels. Parameters
of the SHARF score were collected at the first day that
the criteria of AKI were met. Overall severity was evalu-
ated with the Acute Physiology And Chronic Health
Evaluation II (APACHE II) score [21] and with the
Sequential Organ Failure Assessment (SOFA) score [22]
at admission of the ICU. Short-term outcome para-
meters studied were mortality, ICU and hospital length
of stay (LOS) and renal function at hospital discharge.
Renal function was estimated using the Cockroft and
Gault formula (eGFR) and stages of chronic kidney dis-
ease were defined according to the NKF K/DOQI guide-
lines [23].
Statistical analysis
The data analysis was performed using SPSS, version
12.0 (SPSS Inc, Chicago, Illinois, US).
Outcome parameters studied were hospital mortality,
length of stay in ICU and hospital and renal function at
hospital discharge. Descriptive, univariate analysis was
performed on all parameters in order to find significant
differences between different treatment groups using
Student’s t-test and Chi square test. Multivariate analysis
was performed using logistic regression with mortality
as the dependent outcome variable. Correction for
severity of illness was performed using the SHARF score
as a continuous variable, completed with the APACHE
II and SOFA score. For subgroup analysis, selection was
based on reported evidence that these subgroups
included the most complicated patients showing the
highest co-morbidity and mortality. Confounding factors
were selected if they showed a significant difference in
the comparison between treatment options and contri-
bute effectively and independently to the observed out-
come. Statistical significance was set at the 0.05 level
(two-sided).
Institutional review board
The protocol has been approved initially by the Ethics
Committee of the Stuivenberg Hospital in Antwerp fol-
lowed by the Ethics Committee of each participating
center. A written informed consent has been obtained
from each patient or his representative in case the
patient was unconscious or intubated.
Results
Description of included centers and patients
Nine ICUs participated in the SHARF4 study. Four of
them (Centers 1 to 4 in Table 1) recruited patients dur-
ing the entire three-year study period (April 2001 to
March 2004). One center only started in 2004 and in
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four centers participation ended early due to internal
organizational problems (Other centers in Table 1).
A total of 1,303 patients with AKI, consecutively
admitted to the ICU, were included. Mean age was 64
(range 15 to 96), 63% were male. At baseline, the mean
SHARF score was 62.3 (SD 28.9), APACHE II score 23.9
(SD 10.4) and SOFA score 9.2 (SD 3.9). Basic character-
istics of the overall population with comparison between
the groups with conservative and with RRT treatment
are presented in Table 2.
Treatment modality offered
RRT was initiated in 650 patients (49.9%). Among
patients requiring RRT, 58% received IRRT and 42%
received CRRT at their first day of treatment. Assign-
ment to different treatment options differed significantly
(P < .001) between the SHARF classes as shown in
Figure 1. Within the highest SHARF class, relatively
fewer patients were treated with conservative treatment
and more with CRRT.
Overall outcome in patients with AKI admitted to the ICU
During their hospitalization, 655 out of 1,303 patients
died. Overall observed mortality was 50.3% ranging
from 43 to 64% per center (Table 1). Within the three
classes of the SHARF score, mortality increased from
22% in the lowest class to 64% in the highest class
(Table 3).
Mean ICU LOS was 14 days, mean hospital LOS was
34 days. Within the three classes of the SHARF score,
mean ICU length of stay increased from 7.9 days to 16.0
days. At hospital discharge, patients had a mean eGFR
of 66.6 ml/minute (SD 37.7) and eGFR was above 60
ml/minute (Chronic kidney disease (CKD) stage 1 to 2)
in 39% of patients. On the other hand, 16% of patients
were discharged while still being treated with RRT.
They were considered as having developed end-stage
kidney disease and started a chronic RRT program.
CKD stage 5 at discharge was most frequently observed
in the lowest SHARF class (Table 3).
Comparative outcome in patients with conservative
and RRT treatment
AKI patients that were not treated with RRT showed an
in-hospital mortality of 43% while patients with RRT
Table 1 SHARF score, RRT and Mortality per center
Center n SHARF RRT Mortality
mean (SD) % %
1 158 61.8 (24.3) 45.6 43.0
2 412 58.4 (31.3) 47.8 44.4
3 387 68.8 (27.3) 53.7 55.8
4 223 55.2 (28.3) 54.7 54.7
Others 123 69.2 (27.6) 41.5 53.7
RRT, renal replacement therapy; SHARF score, Stuivenberg Hospital Acute
Renal Failure score
Table 2 Patient characteristics and clinical parameters
Total group Conservative RRT P-value of difference
Number n = 1,303 n = 653 n = 650
Age: mean (range) 66 (15 to 96) 67 (16 to 93) 64 (15 to 96) <.001
Male 63.1% 62.8% 63.5%
Female 36.9% 37.2% 36.5% 0.754
Type of AKI
Pre-renal 45.5% 58.4% 32.6%
Renal 54.5% 41.6% 67.4% <.001
Specified cause of AKI
Acute tubular necrosis 89.6% 89.6% 89.6%
Other 10.4% 10.4% 10.4% 0.997
Setting of AKI
Medical 72.8% 72.2% 73.4%
Surgical 27.2% 27.8% 26.6% 0.634
Severity scores (mean (SD))
SHARF (baseline) 62.3 (28.9) 58.4 (28.4) 66.0 (29.0) <.001
APACHE II (baseline) 23.9 (10.4) 22.5 (10.2) 25.2 (10.4) <.001
SOFA (baseline) 9.2 (3.9) 8.5 (3.8) 9.9 (3.9) <.001
AKI: acute kidney injury RRT: Renal Replacement Therapy SHARF score: Stuivenberg Hospital Acute Renal Failure score [19].
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had an in-hospital mortality of 58% (P < .001). Patients
with RRT treatment showed a higher mortality as well
as a longer ICU and hospital LOS (Figure 2). Even after
a more in-depth correction for disease severity by using
the individual SHARF scores in a logistic regression ana-
lysis, patients treated with RRT showed an increased
risk of mortality of RR = 1.73 (95% CI: 1.4 to 2.2), This
increased risk remained in subgroup analysis and after
exclusion of possible confounders (Figure 3). Additional
correction for confounding by introducing age and sex,
other severity parameters (APACHE II, SOFA), type of
AKI, delayed admission to the ICU and clinical condi-
tions (ventilation, sepsis, heart failure) into the model,
did not alter these results.
In survivors, at hospital discharge, an eGFR of less
than 15 mL/minute (CKD stage 5) was observed in 9%
of patients without RRT compared to 24% in patients
treated with RRT (P < 0.001).
Figure 1 Assignment to different treatment modalities within each SHARF score class. CRRT, continuous renal replacement therapy; IRRT,
intermittent renal replacement therapy.
Table 3 Outcome in total group and according to SHARF severity classes
Overall SHARF score P-value of difference
<30 30-60 >60
Number of AKI patients n = 1303 n = 202 n = 341 n = 688
Hospital mortality 50.3% 21.8% 40.5% 63.7% <0.001
ICU and hospital stay
Days in ICU: mean (SD) 14.1 (16.4) 7.9 (10.0) 13.8 (16.2) 16.0 (17.4) <0.001
Days in hospital: mean (SD) 34.2 (36.6) 29.0 (30.8) 38.8 (43.4) 33.4 (33.7) 0.009
Renal outcome in survivors
CKD stage 1-2 (eGFR > = 60 ml/minute) 38.6% 30.7% 41.4% 43.2%
CKD stage 3 (eGFR 30-59 ml/minute) 35.0% 34.3% 30.8% 39.2%
CKD stage 4 (eGFR 15-29 ml/minute) 10.7% 12.4% 13.0% 7.0%
CKD stage 5 (eGFR <15 ml/minute or ESKD) 15.7% 22.6% 14.8% 10.6% 0.009
AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; SHARF score, Stuivenberg
Hospital Acute Renal Failure score [19].
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Figure 2 Outcome in patients with conservative treatment and renal replacement therapy. LOS, length of stay; RRT, renal replacement
therapy.
Figure 3 Risk of mortality in patients with conservative treatment and renal replacement therapy. Binary logistic regression analysis with
‘without RRT’ as reference category, controlled for disease severity using the SHARF score. A. Predefined subgroup analysis. B. Exclusion of
possible confounders. AKI, acute kidney injury; ICU, intensive care unit; RRT, renal replacement therapy; RR (CI 95%), relative risk with 95%
confidence interval.
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Comparative outcome in patients treated in different
centers
As shown in Table 1, large inter-center differences were
observed in mean SHARF scores (P < .001) as well as in
mortality (P = .003). Particularly in the SHARF 3 class
(that is, patients with the highest disease severity) inter-
center difference in mortality was most pronounced ran-
ging from 48% to 76% (P < .001). RRT frequency
however, did not correspond with mean disease severity
per center. For example, center 1 had the lowest SHARF
score and the highest dialysis frequency.
The influence of center practice with regard to the
initiation of RRT on mortality is shown in Table 4. For
this analysis, centers were ranked according to their
RRT frequency with the lowest taken as reference cen-
ter. Since the ‘other’ centers showed a wide variation in
RRT treatment, this group was excluded from this
analysis. While controlling for individual disease severity
and treatment modality offered (conservative versus
RRT), an increasing center risk of mortality was
observed with increasing use of RRT (overall center
influence P = .032) reaching a OR = 1.9 (95% CI: 1.2 to
2.9) in the center with most RRT treatment.
Discussion
In this multi-center SHARF4 study, including 1,303
consecutively admitted AKI patients, we found signifi-
cant differences in outcome between patients receiving
conservative treatment and those treated with RRT.
Prognosis of RRT patients remained worse, after correc-
tion for disease severity or limiting the analysis to the
most critically ill patients. Center practice of treatment
choice was identified as an independent risk factor for
mortality, with the higher frequency of RRT treatment
associated with higher mortality.
Although our results may be due to differences in
severity of disease in general and renal failure in particu-
lar, no guidelines were available to define this severity
more accurately. The more recently introduced RIFLE
criteria [24] were not yet validated during the study per-
iod [25-27]. We also have no arguments to suspect that
our results are related to the quality of dialysis treat-
ment on itself. Taking into account, the large inter-cen-
ter variation in the decision to start RRT treatment
irrespective of the SHARF score, it will be very difficult
to obtain more conclusive results, particularly based on
observational study designs.
There is still insufficient data to determine absolute
indications and optimal timing for initiation of RRT in
patients with AKI. In some patients, early start of renal
support may improve outcome. However, early initiation
may expose other patients unnecessarily to the risks of
RRT [5]. The AKI Network reviewing the evidence in
this field, stated that ‘the indications for RRT must be
viewed within the context of the patient’s entire clinical
condition with most indications being relative and only
a small number of absolute indications’ [28].
Although well-established recommendations about
initiation of RRT in AKI patients are lacking, one should
at least expect to find some outcome research in this
field. It seems, however, that conservative treatment for
AKI has so far only been considered as the treatment
option for less severe patients. It was never considered
as a meaningful alternative treatment, worthwhile to be
included in research projects comparing outcome in dif-
ferent treatment modalities for AKI. In this regard, the
recently published observations of the VA/NIH Trial are
of particular interest [29]. This clinical trial revealed
that intensive renal support in critically ill AKI patients
did not decrease mortality or improve renal recovery
compared with less intensive therapy.
In our study, the initiation of RRT was at the discre-
tion of the responsible physician, taking into account
the rules of good clinical practice in this field. It looks
however that the balance between the advantages and
disadvantages of starting RRT treatment was interpreted
in a different way in the ICUs participating in the
SHARF study. The difference in center practice is clearly
demonstrated in Table 1 showing no relationship
between the mean SHARF score per center and the per-
centage of patients treated with RRT. This observation
corroborated the more generalized statement of the AKI
Network that the provision of RRT in AKI patients is
extremely variable and based primarily on empiricism
and local institutional practice and resources [28]. The
AKI Network, as well as the Acute Dialysis Quality
Initiative (ADQI) Group two years earlier, emphasized
the high need of additional evidence in this field based
on well-designed trials and observational studies [24,28].
Additionally, cost considerations can also play a more
pronounced role in the decision-making process in the
future. For patients with uncomplicated AKI, it has been
Table 4 Risk of mortality according to center of
treatment
Center influence n % RRT % Mortality RR (95% CI)*
center 1 158 45.6 43.0 ref
center 2 412 47.8 44.4 1.2 (0.8 to 1.8)
center 3 387 53.7 55.8 1.4 (0.9 to 2.1)
center 4 223 54.7 54.7 1.9 (1.2 to 2.9)
* Overall P = .03.
Binary logistic regression analysis with centers ranked according to their
frequency of RRT treatment offered, with the center showing the lowest
frequency of RRT taken as reference category. Center risk was controlled for
individual treatment offered (conservative versus RRT) and individual disease
severity (SHARF score).
RR (95% CI), relative risk with 95% confidence interval; RRT, renal replacement
therapy.
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demonstrated that dialysis therapy was one of the most
prominent factors independently associated with direct
hospital costs and hospital LOS [30].
The clinical trial part of this SHARF 4 study corrobo-
rated the conclusion that benefit with either dialysis
modality could not be observed [20]. Additional com-
parison within and between both treatment options in
respect to delivered dose showed no effect on outcome
[31], as recently also confirmed by a meta-analysis [32].
Since evidence is growing about comparable outcome in
both modalities [10-12,33], also consensus is growing to
merely consider both treatment options as complemen-
tary. On the one hand, there is the opinion that both
techniques can be used interchangeably in critical ill
AKI patients, according to circumstances [34]. Others
stressed that both methods are complementary with
IRRT for faster elimination of electrolytes and waste
products and CRRT for regulation of higher calories
requirements and for hemodynamically unstable patients
[16]. Additionally, it has been mentioned that, although
both treatments have a similar outcome, one or both
has an absolute preference in specific conditions such as
IRRT in patients with specific bleeding risk or CRRT in
patients with cerebral edema or liver failure [5].
Recently, two retrospective cohort studies confirmed
the equal outcome for mortality but revealed a better
renal recovery in patients treated with CRRT [35,36].
We observed the same trend with 28% of IRRT patients
compared to only 18% of CRRT patients with an eGFR
of less than 15 mL/minute (stage 5) at hospital
discharge (P = .107). Questions remain, however, if the
eGFR at hospital discharge can be considered as
the outcome of renal function after AKI. Although at
the time of this study no consensus existed about the
optimal timing to evaluate definitively the renal outcome
after AKI, the presented classification can only be con-
sidered as a preliminary result. A mean hospital LOS of
34 days together with the skewed distribution of this
parameter (range 1 to 339 days) hampered a definitive
classification. Indeed, in our long-term follow-up study
of hospital survivors of this cohort, we observed that 13
out of the 27 patients considered as ESKD at hospital
discharge became dialysis independent, while 7 patients
went on to need chronic dialysis treatment within the
first year after hospital discharge [37].
In this study, we tried to formulate our conclusions
carefully, only stressing the need to re-consider the
value of conservative treatment as a valid and indepen-
dent option in the treatment of AKI. We are aware
about the limitations of our results based on an observa-
tional study design. Particularly concerns arise about the
‘between’ and ‘within’ homogeneity of patients with con-
servative treatment and RRT, as well as about their
equal eligibility for RRT initiation in view of disease
severity. Despite our attempts to control for bias, includ-
ing all available and possible confounders in the multi
variable model, a number of well designed clinical trials
will be needed to obtain more definitive conclusions.
Conclusions
This cohort study of 1,303 AKI patients consecutively
admitted to the ICU confirmed that mortality is equal
in patients treated with intermittent or continuous RRT.
However, prognosis was significantly worse in those
receiving RRT compared to conservative treatment and
this difference remained significant after correction for
the severity of disease and in different subgroup analysis.
A higher mortality was observed in centers with a
higher frequency of RRT treatment. As the indication
for RRT differs between centers and between individual
physicians, this conclusion needs to be validated in
further prospective studies using evidence-based stan-
dards for the indication and timing to initiate RRT.
Meanwhile, and in line with other recent observations,
an integrated and individualized approach, considering
conservative management as well as different RRT
options in each patient, seems to be warranted.
Key messages
• In this cohort study of 1,303 AKI patients consecu-
tively admitted to the ICU, prognosis was signifi-
cantly worse in those receiving RRT compared to
conservative treatment.
• The higher mortality in AKI patients receiving
RRT versus conservative treatment remained signifi-
cant after multiple corrections for severity of disease
and in different subgroups, thus can not only be
explained by a higher disease severity in the RRT
group.
• Within the group of RRT patients, this study con-
firmed that mortality was equal in patients treated
with intermittent or continuous RRT.
• An individualized approach, integrating conserva-
tive management as well as different RRT options in
each patient, deserves more attention.
• Center policy regarding the starting of RRT in AKI
patients admitted to the ICU differed widely in
Belgium.
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